Thermo Fisher Scientific Opens New Manufacturing Facility in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Thermo Fisher Scientific Opens New Manufacturing Facility in China


ePT--the Electronic Newsletter of Pharmaceutical Technology

Thermo Fisher Scientific has officially opened its new manufacturing facility in Suzhou, China. The company has invested nearly $20 million in the 12,000-m2 (129,167 ft2) plant, which will manufacture life-sciences consumables and equipment as well as establish local production capabilities to meet increasing customer demand in China and other regions in Asia Pacific. The new facility will serve the life-sciences and pharmaceutical industries, including research, diagnostics, and bioproduction, and customers in the chemical, environmental, and electronics industries. More than 150 employees will be housed in this facility and there is room for expansion.

In a press statement, Marc Casper, president and CEO of Thermo Fisher Scientific said, “China is one of our fastest-growing markets and has been a key contributor to our success. The Suzhou facility builds on our well-established presence in China and is an important next step as we closely align our depth of capabilities with China’s five-year plan to develop strategic industries, including pharmaceutical, healthcare, and environmental.”

Thermo Fisher entered the Chinese market 30 years ago and will manufacture plastic labware and consumables in Suzhou, including sample preparation products and filterware, as well as laboratory refrigerators, freezers, incubators, and centrifuges. The new facility will adopt best global and local manufacturing practices, including ISO9001, ISO14001, and ISO13485 standards to ensure an environmentally friendly and safe work environment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here